Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

December 3, 2009

Primary Completion Date

September 13, 2012

Study Completion Date

April 16, 2013

Conditions
Chronic Allograft NephropathyChronic Kidney DiseaseChronic Renal FailureDisordered Mineral MetabolismEnd Stage Renal DiseaseHyperparathyroidismHypophosphatemiaKidney DiseaseKidney TransplantationPost Renal Transplantation
Interventions
DRUG

Cinacalcet

Possible sequential doses are 30, 60, 90, 120, and 180 mg.

DRUG

Placebo

Administered orally following the same dosing regimen as the experimental arm.

Trial Locations (51)

1090

Research Site, Vienna

1200

Research Site, Brussels

1211

Research Site, Geneva

2050

Research Site, Camperdown

2145

Research Site, Westmead

3000

Research Site, Leuven

3010

Research Site, Bern

3050

Research Site, Parkville

5011

Research Site, Woodville South

8091

Research Site, Zurich

9000

Research Site, Ghent

10032

Research Site, New York

13353

Research Site, Berlin

16132

Research Site, Genova

18017

Research Site, Bethlehem

20122

Research Site, Milan

24105

Research Site, Kiel

28041

Research Site, Madrid

29010

Research Site, Málaga

30322

Research Site, Atlanta

31403

Research Site, Toulouse

32610

Research Site, Gainesville

33076

Research Site, Bordeaux

34295

Research Site, Montpellier

35128

Research Site, Padua

37232

Research Site, Nashville

44093

Research Site, Nantes

48202

Research Site, Detroit

60201

Research Site, Evanston

60637

Research Site, Chicago

75390

Research Site, Dallas

75743

Research Site, Paris

77030

Research Site, Houston

80045

Research Site, Aurora

85012

Research Site, Phoenix

85284

Research Site, Tempe

94143

Research Site, San Francisco

01107

Research Site, Springfield

T2N 2T9

Research Site, Calgary

V6Z 1Y6

Research Site, Vancouver

N6A 5A5

Research Site, London

K1H 7W9

Research Site, Ottawa

M5C 2T2

Research Site, Toronto

80-952

Research Site, Gdansk

40-027

Research Site, Katowice

90-153

Research Site, Lodz

60-539

Research Site, Poznan

70-111

Research Site, Szczecin

08025

Research Site, Barcelona

08036

Research Site, Barcelona

08907

Research Site, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY